종근당바이오

063160KOSPI

58.4 / 100

Reference Date: 2026-09-08

Financial Score23.0 / 40

News Sentiment20.4 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

CKDBio is a fermentation and biotechnology specialist established in 2001, operating core businesses in API, probiotics, microbiome, and botulinum toxin. Leveraging over 50 years of technical expertise and adherence to global cGMP standards, the company supplies high-value products to over 40 countries. In the botulinum toxin sector, it has secured China NMPA Phase 3 clinical approval, actively expanding its global market presence.

Number of Employees

533people

Average Salary

69.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.59Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-2.24Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

16.37Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲43.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -4.4% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 81.7

Positive
종근당바이오 中 톡신 시장 공략…"품목허가 신청"
종근당바이오의 중국 톡신 시장 진출을 위한 품목허가 신청으로 인해 긍정적인 시장 반응 예상.
Positive
미용에서 치료까지…글로벌 영토 확장 'K-톡신'
종근당바이오의 보툴리눔 톡신 수출 증가와 주요우울증 적응증 임상 승인으로 긍정적인 시장 반응 예상.
Positive
종근당바이오, 보툴리눔 톡신 ‘타임버스’ 중국 품목허가 신청
종근당바이오의 보툴리눔 톡신 '타임버스주' 중국 품목허가 신청으로 인해 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 13,570Won52-week high 24,50052-week low 12,200

1-month return3.0Point

1m -1.45% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral투자판단관련주요경영사항2026-08-14
Neutral반기보고서 (2026.06)2026-08-14